• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Our new sister project AMYPAD officially launches today

2016-10-05News

Today, our new sister project Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) announces the launch of its novel research initiative, bringing together academic and private research partners to investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia.

Beta-amyloid (β-amyloid) deposition in the brain is one of the neuropathological hallmarks on the path towards development of Alzheimer’s disease (AD). The recent advent of commercially available β-amyloid PET tracers has opened up new potential for the visualisation of brain β-amyloid in vivo. It may improve an early diagnosis of AD, and, when recognised in a pre-symptomatic population, even provide an opportunity for secondary prevention of AD. However, the full value of this relatively novel technology and its optimal position in the diagnostic workup of patients is not yet fully understood.

“The AMYPAD Consortium brings together a world-class team of highly synergistic partners from across Europe to form a pan- European network including the most active PET sites. This will ensure effective access to patients and also maximise exposure to technical knowledge and disease modelling. This is a game-changing step in establishing the value of β-amyloid PET imaging in clinical practice”, said Prof Frederik Barkhof, AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Center, Amsterdam and at University College London.

Understanding the value of imaging of β-amyloid using PET provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of people suspected to have AD and their management; 2) understand the natural history of AD in the pre-symptomatic stage; 3) select people for treatment trials aiming at preventing AD by ensuring a more homogeneous and appropriate enrolment. Through engagement with regulators, the AMYPAD consortium will maximise the value of its findings for pharmaceutical companies, healthcare providers, and patients.

AMYPAD will determine in a real-life clinical setting for whom diagnostic β-amyloid imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic certainty, patient management and ultimately decision trees and cost-effectiveness of dementia care.

“The development of β-amyloid imaging has been a tremendous research success which allows a more accurate diagnosis of Alzheimer’s disease and a better selection of research participants for ongoing clinical trials. The AMYPAD project will provide much-needed information on the best place of this new technology in everyday clinical practice. Thanks to projects like these, we hope to get closer to our aim of ensuring a timely and accurate diagnosis for all patients”, said Jean Georges, Executive Director of Alzheimer Europe.

AMYPAD will address the above goals in close collaboration with our EPAD project.

“AMYPAD will apply amyloid PET on an unprecedented scale to patients who are suspected to be in the early stages of AD and generate the knowledge to fully integrate PET β-amyloid markers into current clinical practice in a cost-efficient way, by demonstrating its diagnostic, prognostic and therapeutic value from a multi-stakeholder perspective.”, said Dr Gill Farrar, AMYPAD Project leader and Scientific Director at GE Healthcare Life Sciences.

AMYPAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking.

For more information, contact info@amypad.eu, check out www.amypad.eu or follow @IMI_AMYPAD on Twitter.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the new @AlzheimerEurope report on #DataSharing in #dementia #research, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing. It includes case studies from ADNI, @IMI_EPAD and @IMI_EMIF. ⬇️ Bit.ly/DataSharing_AE twitter.com/AlzheimerEurop…

reply retweet favorite
2:39 pm · 2021-02-23
Twitter
EPAD
EPAD
@IMI_EPAD

Scottish @IMI_EPAD members have been invited to join the first #EPADcommunity meeting. Today, we're discussing about publications, #data access, communications, participant panel, #network & #collaborations. Nice to see some #epadistas sharing their insights 👨‍⚕️👩‍🔬👩‍💻 pic.twitter.com/O1hLAVxk0Q

reply retweet favorite
2:23 pm · 2021-02-17
Twitter
EPAD
EPAD
@IMI_EPAD

The new issue of the @IMI2_NEURONET #newsletter is out with latest news on @IMI_EPAD, @IMI_AMYPAD, @RADARCNS among others. Find out more here: bit.ly/Neuronet-Newsl… twitter.com/IMI2_NEURONET/…

reply retweet favorite
2:12 pm · 2021-02-15
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.